The PBS Update March 2026: Landmark Ipi–Nivo Listing + Toripalimab and Cabozantinib

Send us Fan MailAustralia’s PBS has introduced it’s first pan-tumour reimbursement listing for the immunotherapy combination nivolumab plus ipilimumab. In this inaugural episode of PBS Update, Professor Craig Underhill and Rachael Babin break down the key oncology changes from the March 2026 PBS update, including new listings for toripalimab and cabozantinib.Follow PBS Update for regular discussions on PBS listings and oncology policy changes affecting Australian healthcare professionals.Visit the Show Notes for links to the PBS updates discussed in this episode and to send us audio feedback or questions for future episodes.